87 related articles for article (PubMed ID: 19876945)
1. Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!".
Baiocchi L; Lenci I; Carbone M; Angelico M
Hepatology; 2009 Nov; 50(5):1676-7. PubMed ID: 19876945
[No Abstract] [Full Text] [Related]
2. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
Zeuzem S
J Hepatol; 2008 Aug; 49(2):157-9. PubMed ID: 18554745
[No Abstract] [Full Text] [Related]
3. ADVANCE study begins enrollment.
AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
[No Abstract] [Full Text] [Related]
4. A step forward in therapy for hepatitis C.
Hoofnagle JH
N Engl J Med; 2009 Apr; 360(18):1899-901. PubMed ID: 19403908
[No Abstract] [Full Text] [Related]
5. Successful treatment after short course of telaprevir-based therapy in chronic hepatitis C infected patient.
Dutilh JC; Arends JE
Neth J Med; 2013 Sep; 71(7):391-2. PubMed ID: 24038569
[No Abstract] [Full Text] [Related]
6. Chronic hepatitis C successfully treated with telaprevir, pegylated interferon and ribavirin in severe aplastic anemia.
Balkan II; Bozcan S; Yemisen M; Kutlubay Z; Ozaras R
Ann Hepatol; 2014; 13(6):843-4. PubMed ID: 25332274
[No Abstract] [Full Text] [Related]
7. Treatment of chronic hepatitis C in haemodialysis patients requires more ribavirin.
Slavenburg S; Drenth JP
Nephrol Dial Transplant; 2008 Jul; 23(7):2430; author reply 2430-1. PubMed ID: 18400821
[No Abstract] [Full Text] [Related]
8. Pegylated interferon and ribavirin: A therapeutic option in patients who fail to respond to telaprevir-based triple therapy?
Pascale A; Chazouillères O; Serfaty L
Hepatology; 2013 Aug; 58(2):828. PubMed ID: 23315935
[No Abstract] [Full Text] [Related]
9. Treating hepatitis C: are children the same as adults?
Delgado-Borrego A
Gastroenterology; 2011 Feb; 140(2):389-92. PubMed ID: 21172331
[No Abstract] [Full Text] [Related]
10. Drug rash with eosinophilia and systemic symptoms due to telaprevir.
Montaudié H; Passeron T; Cardot-Leccia N; Sebbag N; Lacour JP
Dermatology; 2010; 221(4):303-5. PubMed ID: 20798484
[TBL] [Abstract][Full Text] [Related]
11. Telaprevir for chronic HCV infection.
Kao JH
N Engl J Med; 2009 Jul; 361(5):534; author reply 534-5. PubMed ID: 19645083
[No Abstract] [Full Text] [Related]
12. Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
Borroni G; Andreoletti M; Casiraghi MA; Ceriani R; Guerzoni P; Omazzi B; Terreni N; Salerno F
Aliment Pharmacol Ther; 2008 May; 27(9):790-7. PubMed ID: 18298638
[TBL] [Abstract][Full Text] [Related]
13. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
Hepatology; 2009 Jun; 49(6):2125; author reply 2125-6. PubMed ID: 19479790
[No Abstract] [Full Text] [Related]
15. [Treatment of chronic hepatitis C].
Fehér J; Lengyel G
Orv Hetil; 2004 May; 145(20):1065-7. PubMed ID: 15202329
[No Abstract] [Full Text] [Related]
16. [Treatment strategies of acute and chronic hepatitis C].
Gładysz A; Inglot M
Przegl Epidemiol; 2002; 56 Suppl 5():10-5. PubMed ID: 15553066
[TBL] [Abstract][Full Text] [Related]
17. [Possible telaprevir-induced pancreatitis. A case study].
Selvi Sabater P; Espuny Miró A; Muñoz Bertrán ED; Plaza Aniorte J
Farm Hosp; 2013; 37(3):269-70. PubMed ID: 23789806
[No Abstract] [Full Text] [Related]
18. Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction.
Keeffe EB
Semin Liver Dis; 2003; 23 Suppl 1():1-2. PubMed ID: 12934161
[No Abstract] [Full Text] [Related]
19. Response-guided therapy: optimizing treatment now and in the future.
Marcellin P; Rizzetto M
Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
[No Abstract] [Full Text] [Related]
20. Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.
Ferenci P; Dusheiko G
Gut; 2014 Jul; 63(7):1033-4. PubMed ID: 24334256
[No Abstract] [Full Text] [Related]
[Next] [New Search]
